Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently amended): A compound represented by the general formula (I):



(I)

wherein,

R^1 and R^2 may be the same or different and each represents an aryl group, heteroaryl group, aryl group substituted with 1 to 3 groups selected from Substituent group α, or heteroaryl group substituted with 1 to 3 groups selected from Substituent group

α;

R^3 represents any one of the following groups:

$-CO-R^4$,

$-CO-O-R^4$,

$-CO-NH-R^4$,

$-CO-CH_2-N(R^a)R^b$,

$-(CH_2)_m-CO-R^5$,

$-(CH_2)_m-R^5$,

$-CO-NH-CO-N(R^a)R^b$,

$-CO-NH-SO_2-N(R^a)R^b$,

$-CO-NH-CO-(CH_2)_m-N(R^a)R^b$, and

$-CO-NH_2$;

R^4 represents a lower alkyl group, cycloalkyl group, cycloalkyl group substituted with 1 to 3 groups selected from Substituent group α, lower alkenyl group, lower alkynyl group, halogeno lower alkyl group, hydroxy lower alkyl group, lower alkoxyalkyl group, lower aliphatic acyloxyalkyl group or lower alkoxycarbonylalkyl group;

R^5 represents a hydroxyl group, a group $-OR^4$, or a group $-N(R^a)R^b$;

R^a and R^b may be the same or different and each represents a

hydrogen atom, hydroxyl group, lower alkoxy group, hydroxy lower alkoxy group, hydroxy lower alkoxyalkyl group, lower alkoxy lower alkoxyalkyl group, cyano lower alkyl group, cyano lower alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxycarbonyl lower alkoxyalkyl group, carbamoyl lower alkyl group, carbamoyl lower alkoxyalkyl group, lower aliphatic acylamino lower alkyl group, lower aliphatic acylamino lower alkoxyalkyl group, lower alkylsulfonylamino lower alkyl group, lower alkylsulfonylamino lower alkoxyalkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkoxyalkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkoxyalkyl group or R^4, or together, including the nitrogen atom to which they are attached, represent a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α;

m represents an integer of 1 to 6;

A represents a methylene group, carbonyl group or sulfonyl group;

B represents a single bond, C_1-C_4 alkylene group or C_2-C_4

alkenylene group;

D represents an oxygen atom or methylene group;

E represents a C_1-C_4 alkylene group or C_2-C_4 alkenylene group;

n represents an integer of 1 to 3; and,

Substituent group α represents a group of substituents consisting of halogen atoms, lower alkyl groups, hydroxy lower alkyl groups, halogeno lower alkyl groups, carboxy lower alkyl groups, lower alkoxy groups, hydroxy lower alkoxy groups, hydroxy lower alkoxyalkyl groups, lower alkoxy carbonyl groups, carboxyl groups, hydroxyl groups, lower aliphatic acyl groups, lower aliphatic acylamino groups, (N-hydroxy-N-methylcarbamoyl) lower alkyl groups, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl groups, hydroxy lower aliphatic acylamino groups, amino groups, carbamoyl groups and cyano groups,

or a pharmacologically acceptable salt ~~or other derivative~~ thereof.

Claims 2-20 (Canceled).

Claim 21 (Previously presented): The compound or

pharmacologically acceptable salt thereof according to claim 1, wherein one of R^a and R^b represents a hydrogen atom, lower alkyl group, hydroxyl group or lower alkoxy group and the other represents a hydroxy lower alkyl group, hydroxy lower alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxy carbonyl lower alkyl group or lower alkoxy carbonyl lower alkoxyalkyl group, or R^a and R^b together, including the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α.

Claim 22 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein $-N(R^a)R^b$ is N-(3-hydroxypropyl)-N-methylamino, N-(4-hydroxybutyl)-N-methylamino, N-(5-hydroxypentyl)-N-methylamino, N-(6-hydroxyhexyl)-N-methylamino, N-[2-(2-hydroxyethoxy)ethyl]-N-methylamino, N-(2-hydroxyethyl)-N-methoxyamino, N-(3-carboxypropyl)-N-methylamino, 2-(3-hydroxypropyl)pyrrolidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, 4-(3-hydroxypropyl)piperidino, 4-(2-hydroxyethoxy)piperidino, 4-

(hydroxyacetamido)piperidino, 4-(2-hydroxyethoxymethyl)piperidino or 4-(2-hydroxyethyl)piperazino.

Claim 23 (Canceled).

Claim 24 (Canceled.

Claim 25 (Previously presented): A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases, allergic diseases and/or urinary incontinence containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to claim 1, in a pharmaceutically acceptable carrier.

Claim 26 (Previously presented): A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence containing an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1, in a pharmaceutically acceptable carrier.

Claim 27 (Previously presented): A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases containing an effective amount of a compound or pharmacologically acceptable salt thereof to claim 1, in a pharmaceutically acceptable carrier.

Claim 28 (Previously presented): A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis and/or chronic obstructive lung disease containing an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1, in a pharmaceutically acceptable carrier.

Claim 29 (Previously presented): The composition according to claim 27 for pulmonary administration.

Claims 30-37 (Canceled).

Claim 38 (Previously presented): A method for preventing or treating respiratory diseases, allergic diseases and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1

to a mammal.

Claim 39 (Previously presented): A method for preventing or treating asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a mammal.

Claim 40 (Previously presented): A method for preventing or treating respiratory diseases by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a mammal.

Claim 41 (Previously presented): A method for preventing or treating asthma, bronchitis and/or chronic obstructive lung disease by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a mammal.

Claim 42 (Previously presented): The method according to claim 40, wherein a compound having the general formula (I) or

pharmacologically acceptable salt thereof is administered by pulmonary administration.

Claim 43 (Previously presented): The method according to claim 37, wherein the mammal is a human.

Claim 44 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein

R^1 is an aryl group or an aryl group substituted with 1 to 3 groups selected from substituent group α,

R^2 is an aryl group substituted with 1 to 3 groups selected from substituent group α,

A is a methylene group or carbonyl group,

B is a single bond or C_1-C_4 alkylene group,

D is an oxygen atom or a methylene group and

E is a C_1-C_4 alkylene group and

wherein one of R^a and R^b represents a hydrogen atom, lower alkyl group, hydroxyl group or lower alkoxy group and the other represents a hydroxy lower alkyl group, hydroxy lower alkoxyalkyl

group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxy carbonyl lower alkyl group or lower alkoxy carbonyl lower alkoxyalkyl group, or R^a and R^b together, including the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group α.

Claim 45 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 44, wherein

R^1 is phenyl or phenyl substituted with 1 to 3 groups selected from substituent group α,

R^2 is a phenyl group substituted with 1 or 2 halogen atoms and

wherein $-N(R^a)R^b$ is N-(3-hydroxypropyl)-N-methylamino, N-(4-hydroxybutyl)-N-methylamino, N-(5-hydroxypentyl)-N-methylamino, N-(6-hydroxyhexyl)-N-methylamino, N-[2-(2-hydroxyethoxy)ethyl]-N-methylamino, N-(2-hydroxyethyl)-N-methoxyamino, N-(3-carboxypropyl)-N-methylamino, 2-(3-hydroxypropyl)pyrrolidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, 4-(3-hydroxypropyl)piperidino, 4-(2-hydroxyethoxy)piperidino, 4-

(hydroxyacetamido)piperidino, 4-(2-hydroxyethoxymethyl)piperidino or 4-(2-hydroxyethyl)piperazino.

Claim 46 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 45, wherein

R^1 is phenyl; or phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups, lower alkoxy groups and hydroxyl groups and

R^3 is $-(CH_2)_m-CO-R^5$.

Claim 47 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 46, wherein

R^1 is phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups and lower alkoxy groups,

R^2 is 3,4-difluorophenyl or 3,4-dichlorophenyl,

R^3 is $-CH_2-CO-N(R^a)R^b$,

R^5 represents a group $-N(R^a)R^b$,

A is a carbonyl group,

B is a single bond, and

E is ethylene or trimethylene.

Claim 48 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 47, wherein

R^1 is 3,5-bis(trifluoromethyl)phenyl or 3,4,5-trimethoxyphenyl

n is 1 or 2 and

R^3 is $-CH_2-CO-N(CH_3)-(CH_2)_4-OH$.

Claim 49 (Previously presented): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl) benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[(morpholin-1-yl)acetyl]oxy})indane-1,4'-piperidine.

Claim 50 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[(morpholin-1-yl)acetyl]oxy})indane-1,4'-piperidine.

Claim 51 (Previously presented): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[bis(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 52 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[bis(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 53 (Previously presented): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[N-(2-hydroxyethyl)-N-methylamino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 54 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein

said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[N-(2-hydroxyethyl)-N-methylamino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 55 (Previously presented): The compound according to claim 1, designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[N-(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 56 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 1-(2-{(2R)-2-(3,4-dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{2-[N-(2-hydroxyethyl)amino]-2-oxoethoxy})indane-1,4'-piperidine.

Claim 57 (Previously presented): The compound according to claim 1, designated
2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-

dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(4-hydroxybutyl)-N-methylacetamide.

Claim 58 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(Trifluoromethyl) benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(4-hydroxybutyl)-N-methylacetamide.

Claim 59 (Previously presented): The compound according to claim 1, designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(3-hydroxypropyl)-N-methylacetamide.

Claim 60 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-

yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]-N-(3-hydroxypropyl)-N-methylacetamide.

Claim 61 (Previously presented): The compound according to claim 1, designated 2-(1-{[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]acetyl}piperidin-4-yl)ethanol.

Claim 62 (Previously presented): The pharmacologically acceptable salt of the compound according to claim 1, wherein said compound is designated 2-(1-{[((2S)-1'-{2-[(2R)-4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl)oxy]acetyl}piperidin-4-yl)ethanol.

Claim 63 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-R^4$.

Claim 64 (Previously presented): The compound or

pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-O-R^4$.

Claim 65 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-NH-R^4$.

Claim 66 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-CH_2-N(R^a)R^b$.

Claim 67 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-(CH_2)_m-CO-R^5$.

Claim 68 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-(CH_2)_m-R^5$.

Claim 69 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1,

wherein R^3 is $-CO-NH-CO-N(R^a)R^b$.

Claim 70 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-NH-SO_2-N(R^a)R^b$.

Claim 71 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-NH-CO-(CH_2)_m-N(R^a)R^b$.

Claim 72 (Previously presented): The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R^3 is $-CO-NH_2$.